C3G

7 registered clinical trials studyying C3G — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease NCT06989359	ADARx Pharmaceuticals, Inc.	Phase 2
Active Not Recruiting	An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Peg NCT05809531	Apellis Pharmaceuticals, Inc.	Phase 3
Completed	Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immun NCT05067127	Apellis Pharmaceuticals, Inc.	Phase 3
Active Not Recruiting	Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN NCT04572854	Apellis Pharmaceuticals, Inc.	Phase 2
Recruiting	Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. NCT04817618	Novartis Pharmaceuticals	Phase 3
Terminated	Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 NCT02682407	Omeros Corporation	Phase 2
Approved For Marketing	C3G/Primary IC-MPGN EAP NCT04729062	Apellis Pharmaceuticals, Inc.	—